At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 159 enrolled
Drug / intervention
Dulaglutide +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 4 Study of Efficacy and Safety of Dulaglutide When Added to Insulin Treatment With or Without Oral Antidiabetic Medication in Patients With Type 2 Diabetes
In Brief
A Phase 4 clinical trial evaluating Dulaglutide and Placebo for Type 2 Diabetes. Completed, enrolled 159 participants across 25 sites.
Detailed Summary
The main purpose of this study is to evaluate the efficacy and safety of combination therapy with dulaglutide and insulin in Japanese participants with type 2 diabetes.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes
CountriesJapan
Collaborators--
Timeline
Phase 4CompletedFinished
2017201820192020202120222023202420252026
First PostedApr 2016
Enrollment StartAug 2016
Primary CompletionJun 2018
TodayJul 2026
First PostedApr 25, 2016
Enrollment StartAug 1, 2016
Primary CompletionJun 18, 2018
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 10.2 years ago
Interventions
Dulaglutidedrug
Administered subcutaneously (SC)
Placebodrug
Administered SC